Published in J Clin Oncol on June 27, 2005
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Risks and benefits of bisphosphonates. Br J Cancer (2008) 1.57
The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc (2007) 1.55
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.36
Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res (2011) 1.32
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev (2012) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone (2010) 1.09
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer (2009) 1.09
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology (2007) 1.08
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer (2011) 1.02
Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02
Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res (2013) 1.02
Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag (2008) 0.97
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.95
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer (2012) 0.94
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat (2014) 0.93
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One (2010) 0.89
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol (2010) 0.87
High bone turnover markers predict poor outcome in patients with bone metastasis. J Clin Oncol (2005) 0.87
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer (2013) 0.87
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res (2008) 0.87
Targeted treatments of bone metastases in patients with lung cancer. Front Oncol (2014) 0.85
Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia (2010) 0.84
A primer of bone metastases management in breast cancer patients. Curr Oncol (2008) 0.84
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res (2010) 0.84
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res (2012) 0.83
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol (2011) 0.83
Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol (2012) 0.83
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst (2014) 0.83
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus (2014) 0.82
Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer. Rev Urol (2014) 0.81
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. Int J Mol Sci (2013) 0.81
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer (2011) 0.81
Pathophysiology of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am (2015) 0.81
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer (2011) 0.81
Bone remodeling markers and bone metastases: From cancer research to clinical implications. Bonekey Rep (2015) 0.80
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. Int J Cancer (2016) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer (2013) 0.79
The role of the bone microenvironment in skeletal metastasis. J Bone Oncol (2012) 0.79
SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol (2016) 0.79
Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth. Mol Cancer Ther (2017) 0.78
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer (2008) 0.78
Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int (2015) 0.78
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials. Oncol Lett (2014) 0.78
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases. Oncologist (2016) 0.78
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer (2011) 0.78
Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis. J Cancer Res Clin Oncol (2014) 0.77
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol (2008) 0.77
The impact of prostate cancer and hormonal therapy on bone. Rev Urol (2009) 0.76
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. J Bone Oncol (2012) 0.76
BMP7: a new bone metastases prevention? Am J Pathol (2007) 0.76
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases. EJNMMI Res (2017) 0.75
Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. J Bone Oncol (2016) 0.75
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. J Natl Med Assoc (2007) 0.75
A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer. J Bone Oncol (2016) 0.75
Risk factors for bone metastasis in patients with primary lung cancer: study protocol for a systematic review. BMJ Open (2014) 0.75
Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges? Curr Oncol (2006) 0.75
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? Breast Care (Basel) (2014) 0.75
Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. J Bone Oncol (2012) 0.75
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer. Breast Cancer (Dove Med Press) (2011) 0.75
Genes, molecules and patients--emerging topics to guide clinical pain research. Eur J Pharmacol (2013) 0.75
Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases. Mol Med Rep (2015) 0.75
Use of urinary markers in cancer setting: A literature review. J Bone Oncol (2015) 0.75
Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy - a randomized trial. BMC Cancer (2016) 0.75
Bone metastases: Causes, consequences and therapeutic opportunities. EJC Suppl (2013) 0.75
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J Bone Oncol (2013) 0.75
RANKL: A promising circulating marker for bone metastasis response. Oncol Lett (2016) 0.75
Prevention and Treatment of Bone Metastases in Breast Cancer. J Clin Med (2013) 0.75
Current approaches to bone-targeted therapy in genitourinary malignancies. Ther Adv Urol (2012) 0.75
The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol (2017) 0.75
Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. J Bone Oncol (2017) 0.75
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging (2016) 0.75
[Clinical relevance of biomarkers in cancer related bone disease]. Wien Med Wochenschr (2007) 0.75
Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling. Bone Res (2017) 0.75
Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol (2007) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
A high-resolution map of active promoters in the human genome. Nature (2005) 24.35
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Superoxide flashes in single mitochondria. Cell (2008) 4.08
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
DNA sequence motifs for structure-specific recognition and separation of carbon nanotubes. Nature (2009) 3.23
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med (2012) 2.25
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest (2008) 2.19
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest (2013) 2.11
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int (2005) 2.11
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer (2003) 2.04
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol (2004) 1.85
Prominent roles of the NorR and Fur regulators in the Escherichia coli transcriptional response to reactive nitrogen species. Proc Natl Acad Sci U S A (2004) 1.81
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res (2010) 1.74
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer (2010) 1.71
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int (2007) 1.68
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 1.68
Discovery of Fur binding site clusters in Escherichia coli by information theory models. Nucleic Acids Res (2007) 1.67
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res (2008) 1.67
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the postpneumococcal conjugate vaccine era. Acad Emerg Med (2008) 1.65
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Subtype-specific alpha1- and beta-adrenoceptor signaling in the heart. Trends Pharmacol Sci (2006) 1.65
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res (2011) 1.64
The aging male population and medical care for benign prostatic hyperplasia in Canada. Can Urol Assoc J (2010) 1.63
Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat (2010) 1.62
Changes to airborne pollen counts across Europe. PLoS One (2012) 1.62
Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology (2009) 1.58
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer (2008) 1.57